Travere Therapeutics, Inc. (NasdaqGM: TVTX)
Health Care · Biotechnology · US
$52.52
+0.76% today · +99.0% 1Y
Travere Therapeutics, Inc. (NasdaqGM: TVTX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $4.91B and employs 497 people.
Over the last twelve months the share price has gained 99.0%, trading between 22.59 and 68.73.
Tweenvest scores Travere Therapeutics, Inc. across four factors: quality 45/100, value 58/100, growth 100/100. Its strongest factor is growth.
TVTX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $4.91B
- Revenue (TTM)
- $591.33M
- P/E
- —
- EPS
- -0.48
- Dividend yield
- —
- Beta (5Y)
- 1.14
- 52-week high
- $68.73
- 52-week low
- $22.59
- Avg volume (3M)
- —
- Shares outstanding
- 94.26M
- Employees
- 497
- Next earnings
- —
About Travere Therapeutics, Inc.
Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral, once-daily, non-immunosuppressive medication targeting two pathways of disease progression (endothelin-1 and angiotensin-II). Sparsentan received accelerated FDA approval in February 2023 and full approval in September 2024 to slow kidney function decline in adults with primary IgA nephropathy (IgAN) at risk of progression. In April 2026, the FDA approved FILSPARI to reduce proteinuria in adult and pediatric patients aged 8 and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome, making it the first and only FDA-approved medicine for FSGS. The company also markets Thiola and Thiola EC (tiopronin tablets) for cystinuria, a rare genetic disorder causing recurring kidney stones. Its pipeline includes pegtibatinase, an investigational enzyme replacement therapy for classical homocystinuria (HCU). Formerly Retrophin, Inc. (renamed November 2020), Travere is headquartered in San Diego, California, and incorporated in Delaware.
- ISIN
- US89422G1076
- Listed since
- Nov 8, 2012
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Scholar Rock Holding CorporationNasdaqGS: SRRK | $5.14B | $42.14 | -0.12% |
| Sunshine Guojian Pharmaceutical (Shanghai) Co., LtdSHSE: 688336 | $5.10B | CN¥38.10 | -8.04% |
| Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.SHSE: 603392 | $5.09B | CN¥26.96 | -1.39% |
| Shanghai RAAS Blood Products Co., Ltd.SZSE: 002252 | $4.98B | CN¥5.06 | -4.89% |
| Chongqing Zhifei Biological Products Co., Ltd.SZSE: 300122 | $4.90B | CN¥13.70 | -2.00% |
| 3SBio Inc.SEHK: 1530 | $4.79B | HK$15.07 | +0.53% |
| Dianthus Therapeutics, Inc.NasdaqCM: DNTH | $4.61B | $82.42 | +0.06% |
| Lin BioScience, Inc.TPEX: 6696 | $4.54B | NT$175.00 | -3.58% |
Figures last refreshed Oct 11, 2026.